Phase I-II Study of Hypofractionated Simultaneous Integrated Boost with Tomotherapy for Prostate Cancer. (Articolo in rivista)

Type
Label
  • Phase I-II Study of Hypofractionated Simultaneous Integrated Boost with Tomotherapy for Prostate Cancer. (Articolo in rivista) (literal)
Anno
  • 2009-01-01T00:00:00+01:00 (literal)
Alternative label
  • Di Muzio N. 1, Fiorino C. 2, Cozzarini C. 1, Alongi F. 1,6, Broggi S. 2, Mangili P. 2, Guazzoni G. 3, Valdagni R. 4, Calandrino R. 2, Fazio F. 1,5,6 (2009)
    Phase I-II Study of Hypofractionated Simultaneous Integrated Boost with Tomotherapy for Prostate Cancer.
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Di Muzio N. 1, Fiorino C. 2, Cozzarini C. 1, Alongi F. 1,6, Broggi S. 2, Mangili P. 2, Guazzoni G. 3, Valdagni R. 4, Calandrino R. 2, Fazio F. 1,5,6 (literal)
Pagina inizio
  • 392 (literal)
Pagina fine
  • 398 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 74 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note
  • Pubblicato on-line: 2 Dicembre 2008. Corresponding author: N. Di Muzio (dimuzio.nadia@hsr.it). IF 2009: 4.592 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1. Departments of Radiotherapy, Scientific Institute San Raffaele, Milano 2. Medical Physics, Scientific Institute San Raffaele, Milano 3. Departments of Urology, Scientific Institute San Raffaele, Milano 4. Prostate Program—Scientific Direction, National Institute of Tumours, Milano 5. Nuclear Medicine, Scientific Institute San Raffaele, Milano 6. IBFM-CNR, Milano (literal)
Titolo
  • Phase I-II Study of Hypofractionated Simultaneous Integrated Boost with Tomotherapy for Prostate Cancer. (literal)
Abstract
  • PURPOSE: To report planning and acute toxicity data of the first 60 patients treated within a Phase I-II study with moderate hypofractionation by image-guided helical tomotherapy. METHODS AND MATERIALS: Various clinical target volumes (CTVs) were defined: CTV1-pelvic nodes; CTV2-upper portion of seminal vesicles; CTV3-lower portion of SV; CTV4-prostate; overlap between planning target volume (PTV) 4 and rectum. Different doses to each PTV were simultaneously delivered in 28 fractions. For 31 low-risk patients: 56.0, 61.6, and 71.4 Gy for PTV2-4, respectively; for 20 intermediate-risk patients: 51.8, 61.6, 65.5, and 74.2 Gy for PTV1-4, respectively; for 9 high-risk patients: 51.8 and 65.5 Gy for PTV1-2 and 74.2 Gy for PTV3-4. For all patients, the dose to overlap was 65.5 Gy. RESULTS: The mean fraction of rectum receiving more than 65 Gy (V65) and rectal Dmax were 10% and 70.8 Gy respectively. In cases of pelvic node irradiation, the intestinal cavity (outside PTV) receiving > 45 and 50 Gy was 86 and 12 cc, respectively. A homogeneous dose distribution within each PTV was guaranteed. Acute genitourinary toxicity according to RTOG scoring system was as follows: 21/60 (35%) Grade 1, 12/60 (20%) Grade 2, 2/60 (3%) Grade 3. Acute rectal toxicities were: 18/60 (30%) Grade 1. Twelve (20%) patients showed Grade 1 upper intestinal toxicity (uGI). No patients experienced >/= Grade 2 acute rectal or uGI side effects. CONCLUSIONS: This study shows excellent results with regard to acute toxicity. Further research is necessary to assess definitive late toxicity and tumor control outcome. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Insieme di parole chiave di
data.CNR.it